Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China
Long Y. Zheng,Chen X. Zhang,Li L. Chen,Yu C. Mao,Jiong Qian,Ping H. Jiang,Jing Deng,Ming G. Shi,Nong Xu
DOI: https://doi.org/10.1016/j.chest.2016.02.327
IF: 9.6
2016-01-01
Chest
Abstract:SESSION TITLE: Lung Cancer III SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Limited data are available on treatment experience in patients with advanced lung adenocarcinoma with unknown EGFR gene status (UN-EGFR-GS). We studied the demographic profile and treatment outcomes of advanced NSCLC patients with adenocarcinoma, which the EGFR gene status was unknown. METHODS: Retrospective study of patients with UN-EGFR-GS advanced lung adenocarcinoma over a 5-year period at a tertiary care institute in China. Patients diagnosed with stage IIIB or IV were included for analysis during 2009 and 2013. And the efficacy of EGFR-TKIs in advanced NSCLC was evaluated in patients with UN-EGFR-GS. RESULTS: In total, 113 patients were included, 95.6% of whom had stage IV disease. Thirty six patients received gemcitabine plus platinum as the first-line treatment, 32 received pemetrexed plus platinum, 11 received EGFR-TKIs and the rest received docetaxel, paclitaxel, novelbine and etc. Forty four patients received oral EGFR-TKIs as the second-line treatment. At the end of follow-up (2015-3-30), 91 patients were dead and 22 patients were alive or lost follow up. The median survival of this whole cohort was 20.0m (95%CI, 16.1m-24.0m,). The overall survival was not associated with the chemotherapy drugs used in the first-line treatment. The patients (19.0m, 95%CI; 11.4m-26.5m) used pemetrexed plus platinum lived no longer than those who used other regimens (20.5m, 95%CI; 13.4m-27.4m) (p=0.272). In the gemcitabine plus platinum group, the median survival was 19.9m (95%CI; 9.2m-30.6m), which was not longer than other groups (20.0m, 95%CI; 15.4m-27.4m) (p=0.404). Those who had a chance to take EGFR-TKIs lived numerically longer than never; the median survival was 24.8m (19.1m-30.5m, 95%CI) and 16.3m (12.7m-19.9m, 95%CI), respectively. However, the overall difference was not significant (p=0.184). CONCLUSIONS: The median survival of patients with advanced lung adenocarcinoma with UN-EGFR-GS was 20m. Oral EGFR-TKIs appear to be useful for this group of patients. CLINICAL IMPLICATIONS: EGFR-TKIs showed to be the oppotunity for the advanced lung adenocarcinoma patients with UN-EGFR-GS. DISCLOSURE: The following authors have nothing to disclose: YuLong Zheng, Xin Xu, Cheng Xiao, ChengYu Mao, Jiong Qian, HaiPing Jiang, Jing Deng, Nong Xu No Product/Research Disclosure Information